Pluri Inc. Common Stock (PLUR) Stock Price

PLURStock

$0.93−79.43%52W

Market Cap$11.73M

P/E—

PEG Ratio—

Div yield—

Beta0.71

PLUR Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-82.07%

Price vs S&P 500 (4W)-11.77%

VGM Score28.45

Book Value / Share (Quarterly)$0.21

P/TBV (Annual)1.89x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)131.94%

Cash Flow / Share (Quarterly)$-1.87

Price vs S&P 500 (YTD)-79.88%

Gross Margin (TTM)40.16%

Net Profit Margin (TTM)-10911.81%

EPS (TTM)$-2.46

10-Day Avg Trading Volume0.01M

EPS Excl Extra (TTM)$-2.46

Revenue Growth (5Y)41.83%

EPS (Annual)$-2.44

ROI (Annual)-86.59%

Gross Margin (Annual)44.59%

Net Profit Margin (5Y Avg)-30867.06%

Cash / Share (Quarterly)$0.72

Revenue Growth QoQ (YoY)-37.93%

ROA (Last FY)-95.75%

Revenue Growth TTM (YoY)-20.87%

EBITD / Share (TTM)$-2.51

ROE (5Y Avg)-99.22%

Operating Margin (TTM)-10118.11%

Cash Flow / Share (Annual)$-1.87

P/B Ratio266.82x

P/B Ratio (Quarterly)2.84x

Net Income / Employee (Annual)$-187,600

EV / Revenue (TTM)39.60x

Net Interest Coverage (TTM)-66.54x

ROA (TTM)-82.71%

EPS Growth QoQ (YoY)35.93%

EPS Incl Extra (Annual)$-2.44

Current Ratio (Annual)0.27x

Quick Ratio (Quarterly)0.27x

3-Month Avg Trading Volume0.03M

52-Week Price Return-79.43%

Revenue / Employee (TTM)$2,065,041,000

Tangible BV / Share (Quarterly)$0.21

P/S Ratio (Annual)11.54x

Asset Turnover (Annual)0.04x

52-Week High$4.87

Operating Margin (5Y Avg)-30847.83%

EPS Excl Extra (Annual)$-2.44

CapEx CAGR (5Y)-5.19%

Tangible BV CAGR (5Y)-14.07%

26-Week Price Return-72.16%

Quick Ratio (Annual)0.25x

13-Week Price Return-50.01%

Total Debt / Equity (Annual)250.28x

Current Ratio (Quarterly)0.27x

Enterprise Value$36.42M

Revenue / Share Growth (5Y)10.64%

Asset Turnover (TTM)0.00x

Book Value / Share Growth (5Y)-33.61%

Revenue / Employee (Annual)$8,000

Pretax Margin (Annual)-2499.41%

Cash / Share (Annual)$0.72

3-Month Return Std Dev70.26%

Gross Margin (5Y Avg)88.18%

Net Income / Employee (TTM)$-187,600

ROE (Last FY)-21758.33%

Net Interest Coverage (Annual)-16.32x

EPS Basic Excl Extra (Annual)$-2.44

Receivables Turnover (TTM)0.46x

Total Debt / Equity (Quarterly)260.33x

EPS Incl Extra (TTM)$-2.46

Receivables Turnover (Annual)3.81x

ROI (TTM)-61.52%

P/S Ratio (TTM)99.62x

Pretax Margin (5Y Avg)-30867.06%

Revenue / Share (Annual)$0.10

Tangible BV / Share (Annual)$0.32

Price vs S&P 500 (52W)-94.96%

EPS Growth TTM (YoY)35.10%

Year-to-Date Return-68.90%

5-Day Price Return-4.12%

EPS Normalized (Annual)$-2.44

ROA (5Y Avg)-60.85%

Net Profit Margin (Annual)-2344.59%

Month-to-Date Return-7.01%

Cash Flow / Share (TTM)$-0.70

EBITD / Share (Annual)$-2.51

Operating Margin (Annual)-2454.53%

LT Debt / Equity (Annual)250.28x

ROI (5Y Avg)-71.37%

LT Debt / Equity (Quarterly)260.33x

EPS Basic Excl Extra (TTM)$-2.46

P/TBV (Quarterly)2.84x

P/B Ratio (Annual)323.05x

Pretax Margin (TTM)-10911.81%

Book Value / Share (Annual)$0.02

Price vs S&P 500 (13W)-52.69%

Beta0.71x

Revenue / Share (TTM)$0.01

ROE (TTM)-53.15%

52-Week Low$0.85

vGradeF

gGradeC

mGradeD

vgmGradeD

PLUR Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q3 2025	Nov 12, 2025	-$0.74	-$0.65	+12.16%(+$0.09)
Q2 2025	Sep 17, 2025	-$0.73	-$1.00	-36.99%(-$0.27)
Q1 2025	May 13, 2025	—	-$0.94	—

PLUR Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.14

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
PLURPluri Inc. Common Stock	F	C	D	99.6x	-20.9%	40.2%	—	$0.93
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74

About Pluri Inc. Common Stock

Pluri Inc develops cell-based therapeutics using its proprietary 3D cell expansion platform, targeting regenerative medicine, immunotherapy, and hematologic diseases. The company generates revenue through CDMO services while advancing placenta-derived cell therapy candidates for inflammatory and musculoskeletal conditions. Pluri is also exploring applications in cultivated alternative proteins.